Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05099120
Other study ID # Jingwen Wang
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2010
Est. completion date December 31, 2024

Study information

Verified date August 2021
Source Xijing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Serious infections refer to life-threatening infections with a morbidity and mortality rate of up to 50%, and are the main cause of death in critically ill patients, mainly including systemic inflammatory response syndrome, sepsis, infectious shock, or systemic multiple organ dysfunction syndrome. Patients with severe infections have rapid disease development, which can cause disorders of cellular circulation and metabolism and impairment of multi-organ function in the early stage, mostly accompanied by clinical complications, and despite the progress of medical technology and the popularization of antibiotic application, the mortality and disability rate is high, which is a hot spot of clinical research today. Patients with severe infections are exposed to a wide range of medical risk factors, including patient factors (advanced age, frailty, malnutrition, long hospital stay, prolonged bed rest), disease factors (immune deficiency, malignancy, diabetes, renal failure, liver failure), drug factors (long-term use of steroid hormones, chemotherapeutic drugs, NSAIDs, etc.), interventional factors (central venous catheter, recent invasive surgery, hemodialysis, endotracheal intubation or mechanical ventilation, etc.), which bring great challenges to clinical treatment. Therefore, early identification of risk indicators for deterioration of infected patients provides a strategic basis for the medical team to take early warning measures to prevent deterioration and poor prognosis, and to reduce the risk of deterioration of patients, which is also the key to reduce the risk of death of infected patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 16000
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients diagnosed with infection Exclusion Criteria: - Case information is incomplete - Do not accept follow-up

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Among patients with infections admitted to the hospital primary outcome measure were defined as the death. 30 days of hospitalization
See also
  Status Clinical Trial Phase
Recruiting NCT06055777 - Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts Phase 1
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Recruiting NCT05793983 - S100A8/A9 and Innate Immunity in Liver Disease
Active, not recruiting NCT05963269 - The Effect of the Game on Students' Intramuscular Injection Skills N/A
Not yet recruiting NCT06026852 - Validation of Betalactam ML Prediction Models - TDMAide N/A
Not yet recruiting NCT02222779 - Quantification of Transition Metals N/A
Completed NCT01976234 - Stored RBC Transfusion and Immonomodulation N/A
Completed NCT01530763 - Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Phase 2/Phase 3
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Completed NCT01158560 - A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Phase 3
Completed NCT01176786 - Reusable Versus Disposable Draping System in Breast Reconstruction Surgery N/A
Active, not recruiting NCT05284097 - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Phase 2
Enrolling by invitation NCT06055712 - Antibiotic Prophylaxis in Pediatric Open Fractures Phase 4
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Not yet recruiting NCT06402292 - Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute N/A
Recruiting NCT06002685 - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention N/A
Completed NCT02802059 - E. Coli Nissle 1917 - Suspension for Infection Prophylaxis Phase 3
Completed NCT05289674 - The Effect of Lactoferrin in High Calorie Formula on IL-6 and IL10 in Children With Failure to Thrive and Infection N/A
Recruiting NCT05770765 - Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases
Completed NCT05389540 - Rural South and Southeast Asia Household Health Survey